{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02462330",
      "OrgStudyIdInfo": {
        "OrgStudyId": "10 142 01"
      },
      "Organization": {
        "OrgFullName": "University Hospital, Toulouse",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy (MESAMI2)",
      "OfficialTitle": "Effect of Intramyocardial Mesenchymal Stem Cells Injection in Patients With Chronic Ischemic Cardiomyopathy and Left Ventricular Dysfunction Guide by NogaStar XP System Catheter.",
      "Acronym": "MESAMI2"
    },
    "StatusModule": {
      "StatusVerifiedDate": "October 2021",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "February 19, 2016",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "May 27, 2015",
      "StudyFirstSubmitQCDate": "June 1, 2015",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "June 4, 2015",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "October 27, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 28, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "University Hospital, Toulouse",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Stem cell therapy is an emerging treatment for cardiovascular disease but the best cell type and delivery method remain to be determined. Pre-clinical studies demonstrated improvement of cardiac function by Mesenchymal stem cells (MSC) therapy in particular by their paracrine and immunosuppressive properties. Investigators initiated the MESAMI program by the bicentric pilot phase and highlighted the safety and feasibility of intramyocardial injections of MSCs from bone marrow in patients with chronic ischemic cardiomyopathy and left ventricular dysfunction, guide by the NOGA-XP system. The MESAMI program continues with the phase 2, multicenter, double-blind, randomized, placebo-controlled trial.The aim of this phase 2 study is to demonstrate a functional improvement, measuring peak VO2, at 3 months between the cell therapy group and the placebo group.",
      "DetailedDescription": "Ischemic cardiomyopathies are a leading cause of death in both men and women. During the last decade, treatments for heart failure have evolved, but their purpose is to improve symptoms and prevent aggravation of the disease. Current research is focusing on the development of cell-based therapies using different sources of stem cells which can provide trophic and paracrine support or even replace dying cells with new ones. A specific form of stem cells, called adult mesenchymal stem cells (MSCs), has shown promise for heart repair. These cells are known for their ability to secrete paracrine factors and their immunosuppressive properties. The MESAMI 2 study will evaluate the efficacy of MSCs injection directly into the heart to repair and restore heart function in people with chronic ischemic heart failure using NOGA-XP system.\n\nThis phase 2 study is a prospective, multicenter, double-blind, randomized, placebo-controlled trial. A total of 90 patients will be randomized in 2 arms to receive intramyocardial injection of MSCs or placebo. Patients will be followed up for 13 months. Bone marrow will be collected and immediately transported to the French Blood Establishment for MSC isolation and expansion. Patients will receive intramyocardial injection of MSCs or placebo during a left heart catheterization."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Chronic Myocardial Ischemia"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Mesenchymal stem cells",
          "ischemic cardiomyopathy",
          "NogaStar XP system catheter"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Double",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "90",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Placebo comparator",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "injection of human albumin 4%",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Placebo comparator"
              ]
            }
          },
          {
            "ArmGroupLabel": "Autologous MSC from bone marrow",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "intramyocardial injection of 6.10e7 stem cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Autologous MSC from bone marrow"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Autologous MSC from bone marrow",
            "InterventionDescription": "After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Autologous MSC from bone marrow"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "mesenchymal stem cells"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Placebo comparator",
            "InterventionDescription": "injections of human albumin",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo comparator"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Human Albumin"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Change in VO2max",
            "PrimaryOutcomeDescription": "Change in VO2max (or peak VO2) before injection and at 3 months post injection.",
            "PrimaryOutcomeTimeFrame": "3 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Left ventricular viability",
            "SecondaryOutcomeDescription": "MRI",
            "SecondaryOutcomeTimeFrame": "Before injection and at 3, 6 and 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "NYHA/CCS class",
            "SecondaryOutcomeDescription": "Change on class",
            "SecondaryOutcomeTimeFrame": "Before injection and at 3, 6 and 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Quality of life (Minnesota questionnaire)",
            "SecondaryOutcomeDescription": "Change on quality of life test score",
            "SecondaryOutcomeTimeFrame": "Before injection and at 3, 6 and 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "VO2 max",
            "SecondaryOutcomeDescription": "Change in VO2max (or peak VO2) at 6 and 12 months post injection.",
            "SecondaryOutcomeTimeFrame": "At 6 and 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "6'walking-test",
            "SecondaryOutcomeDescription": "Distance to walk test",
            "SecondaryOutcomeTimeFrame": "Between 3 and 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Echocardiography",
            "SecondaryOutcomeDescription": "Volume of myocardium and measurement of ejection fraction",
            "SecondaryOutcomeTimeFrame": "Before injection and at 3, 6 and 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Myocardial perfusion imaging",
            "SecondaryOutcomeDescription": "Efficacy of the cell therapy on LVEF",
            "SecondaryOutcomeTimeFrame": "Before injection and at 3, 6 and 12 months"
          },
          {
            "SecondaryOutcomeMeasure": "BNP blood test",
            "SecondaryOutcomeDescription": "Change of the BNP blood test at 3, 6 and 12 months",
            "SecondaryOutcomeTimeFrame": "Before injection and at 3, 6 and 12 months"
          }
        ]
      },
      "OtherOutcomeList": {
        "OtherOutcome": [
          {
            "OtherOutcomeMeasure": "Adverse event related to cell administration",
            "OtherOutcomeTimeFrame": "12 months"
          },
          {
            "OtherOutcomeMeasure": "Complication related to cell administration",
            "OtherOutcomeTimeFrame": "12 months"
          },
          {
            "OtherOutcomeMeasure": "Control of the implantable cardioverter defibrillator",
            "OtherOutcomeTimeFrame": "12 months"
          },
          {
            "OtherOutcomeMeasure": "Analysis of major cardiovascular events",
            "OtherOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatient who signed the informed consent,\nChronic stable ischemic cardiomyopathy for at least one month with a NYHA Class II-IV and/or -Angina pectoris CCS Class III or IV,\nNot a candidate for revascularization by coronary artery by-pass surgery or angioplasty,\nLeft ventricular function ≤45%,\nPresence of ischemia or myocardial viability on the myocardial perfusion imaging,\nVO2 max≤ 20 ml/min/kg,\nOptimal medical therapy,\nOptimal interventional therapy (Implantable Cardiovertor Defibrillator, effort rehabilitation).\n\nExclusion criteria:\n\nPregnancy or breastfeeding,\nAcute coronary syndrome or myocardial infarction during the last 3 months,\nRevascularization (PCI or CABG), or cardiac resynchronization during the last 3 months,\nFurther revascularization planned for the next 30 days,\nLVEF >45%,\nLeft intraventricular Thrombus and / or ventricular aneurysm detected by transthoracic echocardiography,\nWall thickness in the target region <8 mm as determined by echocardiography,\nCritical Limb Ischemia stages 3 or 4,\nInability to achieve a VO2 test,\nNot feasible peripheral arterial access for percutaneous procedure,\nAortic stenosis (<1cm²) or aortic insufficiency (> 2 +),\nPatients with transplanted organ,\nChronic renal failure with creatinemia ≥ 250 µmol/L,\nSevere hepatic dysfunction,\nChronic atrial fibrillation,\nDecompensated heart failure,\nUncontrolled Ventricular arrhythmias,\nIndication of cardiac resynchronization by multisite pacemaker or cardiac resynchronization during the last 3 months,\nObesity preventing bone marrow aspiration or manual compression of the puncture area after bone marrow collection,\nActive uncontrolled infection\nImmuno-modulator treatment (ciclosporin, mycophenolate, mycophenolate mofetil, azathioprine, tacrolimus, anthracyclines, neupogen, hydrea, etanercept interferons, prednisolone, methylprednisolone, colchicine),\nHistory of cancer in the last 5 years,\nHemopathy, hematopoietic disease,\nHaemorrhagic syndrome,\nChronic or progressive disease that may alter the prognosis within 3 months,\nPositive serologies for Human immunodeficiency virus (HIV1-2), HTLV-1 (human T-cell lymphotrophic virus) and 2, HBV (hepatitis B virus) or HCV (hepatitis B virus).\nAllergic to xylocain.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Jerôme Roncalli, MD, PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "05 61 32 26 13",
            "CentralContactPhoneExt": "+33",
            "CentralContactEMail": "roncalli.j@chu-toulouse.fr"
          },
          {
            "CentralContactName": "Amandine Pauze",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "05 61 77 84 34",
            "CentralContactEMail": "pauze.a@chu-toulouse.fr"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Jerôme Roncalli, MD, PhD",
            "OverallOfficialAffiliation": "Toulouse University Hospital",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "University hospital of Henri Mondor",
            "LocationStatus": "Recruiting",
            "LocationCity": "Créteil",
            "LocationZip": "94010",
            "LocationCountry": "France",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Emmanuel Teiger, MD, PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "01 49 81 21 11",
                  "LocationContactPhoneExt": "+33",
                  "LocationContactEMail": "emmanuel.teiger@hmn.aphp.fr"
                },
                {
                  "LocationContactName": "Emmanuel Teiger, MD, PhD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          },
          {
            "LocationFacility": "University hospital of Grenoble",
            "LocationStatus": "Not yet recruiting",
            "LocationCity": "Grenoble",
            "LocationZip": "38043",
            "LocationCountry": "France",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Yannick Neuder",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "04 76 76 84 66",
                  "LocationContactPhoneExt": "+33",
                  "LocationContactEMail": "YNeuder@chu-grenoble.fr"
                },
                {
                  "LocationContactName": "Yannick Neuder, MD, PhD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          },
          {
            "LocationFacility": "University hospital of Lille",
            "LocationStatus": "Not yet recruiting",
            "LocationCity": "Lille",
            "LocationZip": "59037",
            "LocationCountry": "France",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Eric Van Belle, MD, PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "03 20 44 59 62",
                  "LocationContactPhoneExt": "+33",
                  "LocationContactEMail": "ericvanbelle@aol.com"
                },
                {
                  "LocationContactName": "Eric Van Belle, MD, PhD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          },
          {
            "LocationFacility": "University hospital of Nantes",
            "LocationStatus": "Not yet recruiting",
            "LocationCity": "Nantes",
            "LocationZip": "44093",
            "LocationCountry": "France",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Jean-Noël Trochu, MD, PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "02 40 16 52 77",
                  "LocationContactPhoneExt": "+33",
                  "LocationContactEMail": "jeannoel.trochu@chu-nantes.fr"
                },
                {
                  "LocationContactName": "Jean-Noël Trochu, MD, PhD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          },
          {
            "LocationFacility": "University hospital of Pitié-Salpêtrière",
            "LocationStatus": "Recruiting",
            "LocationCity": "Paris",
            "LocationZip": "75651",
            "LocationCountry": "France",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Richard Isnard, MD, PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "01 42 16 30 09",
                  "LocationContactPhoneExt": "+33",
                  "LocationContactEMail": "richard.isnard@psl.aphp.fr"
                },
                {
                  "LocationContactName": "Richard Isnard, MD, PhD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          },
          {
            "LocationFacility": "Cardiology Department of Rangueil Hospital - Rangueil Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Toulouse",
            "LocationZip": "31059",
            "LocationCountry": "France",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Jerôme Roncalli, MD, PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "05 61 32 26 13",
                  "LocationContactPhoneExt": "+33",
                  "LocationContactEMail": "roncalli.j@chu-toulouse.fr"
                },
                {
                  "LocationContactName": "Marine Lebrin",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "05 61 32 37 24",
                  "LocationContactPhoneExt": "+33",
                  "LocationContactEMail": "lebrin.m@chu-toulouse.fr"
                },
                {
                  "LocationContactName": "Jerôme Roncalli, MD, PhD",
                  "LocationContactRole": "Principal Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009202",
            "ConditionMeshTerm": "Cardiomyopathies"
          },
          {
            "ConditionMeshId": "D000017202",
            "ConditionMeshTerm": "Myocardial Ischemia"
          },
          {
            "ConditionMeshId": "D000007511",
            "ConditionMeshTerm": "Ischemia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000006331",
            "ConditionAncestorTerm": "Heart Diseases"
          },
          {
            "ConditionAncestorId": "D000002318",
            "ConditionAncestorTerm": "Cardiovascular Diseases"
          },
          {
            "ConditionAncestorId": "D000014652",
            "ConditionAncestorTerm": "Vascular Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M9695",
            "ConditionBrowseLeafName": "Ischemia",
            "ConditionBrowseLeafAsFound": "Ischemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M5698",
            "ConditionBrowseLeafName": "Coronary Artery Disease",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M18658",
            "ConditionBrowseLeafName": "Myocardial Ischemia",
            "ConditionBrowseLeafAsFound": "Myocardial Ischemia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11306",
            "ConditionBrowseLeafName": "Cardiomyopathies",
            "ConditionBrowseLeafAsFound": "Cardiomyopathy",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M19977",
            "ConditionBrowseLeafName": "Ventricular Dysfunction",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M19744",
            "ConditionBrowseLeafName": "Ventricular Dysfunction, Left",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8571",
            "ConditionBrowseLeafName": "Heart Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M16552",
            "ConditionBrowseLeafName": "Vascular Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC14",
            "ConditionBrowseBranchName": "Heart and Blood Diseases"
          }
        ]
      }
    }
  }
}